Grufity logoGrufity logo
Stock Ideas
New
StocksFundsScreenerSectorsWatchlists
GILD

GILD - Gilead Sciences Inc Stock Price, Fair Value and News

64.78USD-0.55 (-0.84%)Market Closed

Market Summary

GILD
USD64.78-0.55
Market Closed
-0.84%

GILD Alerts

  • 1 major insider sales recently.

GILD Stock Price

View Fullscreen

GILD RSI Chart

GILD Valuation

Market Cap

80.7B

Price/Earnings (Trailing)

14.25

Price/Sales (Trailing)

2.98

EV/EBITDA

11.99

Price/Free Cashflow

10.87

GILD Price/Sales (Trailing)

GILD Profitability

EBT Margin

25.30%

Return on Equity

24.81%

Return on Assets

9.12%

Free Cashflow Yield

9.2%

GILD Fundamentals

GILD Revenue

Revenue (TTM)

27.1B

Rev. Growth (Yr)

-3.72%

Rev. Growth (Qtr)

0.89%

GILD Earnings

Earnings (TTM)

5.7B

Earnings Growth (Yr)

-12.84%

Earnings Growth (Qtr)

-34.43%

Breaking Down GILD Revenue

Last 7 days

-1.0%

Last 30 days

-8.6%

Last 90 days

-15.8%

Trailing 12 Months

-17.5%

How does GILD drawdown profile look like?

GILD Financial Health

Current Ratio

1.43

Debt/Equity

1.02

Debt/Cashflow

0.35

GILD Investor Care

Dividend Yield

4.63%

Dividend/Share (TTM)

3

Buy Backs (1Y)

0.11%

Diluted EPS (TTM)

4.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202327.0B27.4B27.4B27.1B
202227.5B27.5B27.1B27.3B
202125.6B26.6B27.5B27.3B
202022.7B22.2B23.1B24.7B
201922.3B22.4B22.4B22.4B
201824.7B23.2B22.3B22.1B
201729.1B28.5B27.5B26.1B
201632.8B32.4B31.6B30.4B
201527.5B29.2B31.4B32.6B
201413.7B17.4B20.7B24.9B
201310.0B10.3B10.7B11.2B
20128.7B9.0B9.3B9.7B
20117.8B8.0B8.2B8.4B
20107.6B7.8B8.0B7.9B
20095.6B6.0B6.4B7.0B
200804.6B5.0B5.3B
20070004.2B
Get all data in R, Python etc through our Historical Stock Data APIs
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Gilead Sciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 25, 2024
telman deborah h
acquired
-
-
515
evp, corporate affairs & gc
Apr 25, 2024
telman deborah h
sold (taxes)
-10,312
65.27
-158
evp, corporate affairs & gc
Apr 01, 2024
parsey merdad
sold
-145,920
72.96
-2,000
chief medical officer
Mar 10, 2024
patterson sandra
acquired
-
-
2,682
svp, controllership
Mar 10, 2024
mercier johanna
sold (taxes)
-342,472
75.12
-4,559
chief commercial officer
Mar 10, 2024
mercier johanna
acquired
-
-
9,844
chief commercial officer
Mar 10, 2024
telman deborah h
sold (taxes)
-63,551
75.12
-846
evp, corporate affairs & gc
Mar 10, 2024
parsey merdad
acquired
-
-
10,401
chief medical officer
Mar 10, 2024
dickinson andrew d
sold (taxes)
-338,416
75.12
-4,505
chief financial officer
Mar 10, 2024
telman deborah h
acquired
-
-
2,555
evp, corporate affairs & gc

1–10 of 50

Which funds bought or sold GILD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 02, 2024
FinTrust Capital Advisors, LLC
added
92.42
41,117
96,690
 0.02%
May 02, 2024
AlphaQ Advisors LLC
reduced
-18.46
-144,449
405,366
 0.24%
May 02, 2024
Bryn Mawr Capital Management, LLC
reduced
-1.75
-25,779
205,100
 0.01%
May 02, 2024
Apollon Wealth Management, LLC
reduced
-5.83
-421,309
2,416,200
 0.08%
May 02, 2024
Sumitomo Mitsui DS Asset Management Company, Ltd
added
3.74
-733,860
11,106,200
 0.14%
May 02, 2024
BARON SILVER STEVENS FINANCIAL ADVISORS, LLC
added
1.04
-90,759
959,941
 0.19%
May 02, 2024
PITTENGER & ANDERSON INC
sold off
-100
-36,455
-
 -%
May 02, 2024
Blume Capital Management, Inc.
unchanged
-
-27,316
257,840
 0.06%
May 02, 2024
Proficio Capital Partners LLC
added
2.39
-18,811
231,860
 0.03%
May 02, 2024
KESTRA PRIVATE WEALTH SERVICES, LLC
reduced
-9.53
-687,666
3,091,040
 0.07%

1–10 of 50

Are Funds Buying or Selling GILD?

Are funds buying GILD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GILD
No. of Funds

GILD Alerts

Unveiling Gilead Sciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.97%
111,820,711
SC 13G/A
Feb 09, 2024
capital world investors
6.7%
83,698,215
SC 13G/A
Jan 24, 2024
blackrock inc.
9.9%
122,790,297
SC 13G/A
Feb 13, 2023
capital world investors
5.5%
68,900,998
SC 13G
Feb 13, 2023
capital research global investors
4.4%
54,602,952
SC 13G/A
Feb 09, 2023
vanguard group inc
8.93%
112,038,324
SC 13G/A
Jan 31, 2023
blackrock inc.
10.5%
131,555,769
SC 13G/A
Jul 08, 2022
blackrock inc.
10.1%
126,932,693
SC 13G
Feb 11, 2022
capital research global investors
8.5%
107,156,981
SC 13G/A
Feb 10, 2022
vanguard group inc
8.43%
105,803,799
SC 13G/A

Recent SEC filings of Gilead Sciences Inc

View All Filings
Date Filed Form Type Document
May 02, 2024
SC 13D/A
13D - Major Acquisition
Apr 26, 2024
4
Insider Trading
Apr 25, 2024
8-K
Current Report
Apr 19, 2024
3
Insider Trading
Apr 19, 2024
SC 13G
Major Ownership Report
Apr 05, 2024
SC 13G
Major Ownership Report
Apr 03, 2024
3
Insider Trading
Apr 03, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 01, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Gilead Sciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
JNJ
359.2B
85.6B
 -3.24% -7.94%
9.34
4.19
 5.68% 202.39%
MRK
323.0B
61.4B
 -1.84% 8.64%
140.05
5.26
 6.11% -82.30%
AMGN
166.9B
29.5B
 13.40% 34.20%
44.36
5.65
 12.76% -52.47%
PFE
157.1B
46.5B
 2.20% -27.23%
-113.14
3.37
 42.59% -114.62%
GILD
80.7B
27.1B
 -8.62% -17.50%
14.25
2.98
 -0.60% 23.36%
TEVA
15.6B
15.8B
 -0.99% 61.25%
-27.18
0.99
 6.17% 76.47%
MID-CAP
PRGO
4.4B
4.7B
 5.70% -11.21%
-349.99
0.95
 4.58% 90.97%
ALKS
4.1B
1.7B
 -8.55% -16.13%
9.38
2.36
 54.01% 364.56%
BHC
2.9B
9.0B
 -22.11% 32.77%
-6.3
0.32
 10.01% -27.45%
AMPH
2.0B
644.4M
 1.22% 16.11%
14.84
3.17
 29.14% 50.51%
SMALL-CAP
TLRY
1.6B
743.2M
 -26.67% -17.06%
-4.6
2.18
 24.65% 80.36%
TXMD
22.0M
1.3M
 -14.35% -52.84%
-2.14
16.92
 -98.14% -109.18%
ACRX
17.1M
-
 - 62.93%
-0.93
0.22
 2882.68% -138.52%
AGRX
2.5M
19.6M
 35.71% -93.63%
-0.17
0.13
 80.00% 43.08%
ACOR
1.1M
117.6M
 -94.70% -92.62%
0
0.01
 -0.79% -283.60%

Gilead Sciences Inc News

Latest updates
MarketBeat • 6 hours ago
Amalgamated Bank Sells 19,072 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
MarketBeat • 6 hours ago
Gilead Sciences (NASDAQ:GILD) Sets New 1-Year Low at $64.42
MarketWatch • 14 hours ago
Gilead Sciences Inc. stock underperforms Friday when compared to competitors
MarketWatch • 38 hours ago
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
MarketWatch • 01 May 2024 • 08:45 pm
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Yahoo Finance • 30 Apr 2024 • 04:01 pm
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
Zacks Investment Research • 29 Apr 2024 • 02:02 pm
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Yahoo Finance • 12 Apr 2024 • 07:00 am
Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know
Yahoo Finance • 20 Mar 2024 • 07:00 am
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Yahoo Finance • 2 months ago
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Gilead Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue0.9%7,1147,0516,5996,3527,3897,0426,2606,5907,2447,4216,2176,4237,4216,5775,1435,5485,8795,6045,6855,2815,795
Costs and Expenses24.3%5,5024,4284,9344,6475,1224,2054,2316,3936,3043,5793,9713,5334,7704,5768,1263,1464,7867,0773,2553,0444,651
  S&GA Expenses22.2%1,6081,3151,8491,3192,0201,2131,3571,0831,6501,1901,3511,0551,7301,1061,2391,0761,2041,0521,0951,0301,131
  R&D Expenses----------------1,1011,8994,9901,1601,0571,950
EBITDA Margin-3.1%0.30*0.31*0.31*0.32*0.26*0.21*0.25*0.26*0.35*0.39*0.30*----------
Interest Expenses8.6%252232230230226229242238238250256257267236240241243250248254257
Income Taxes62.0%237146549316398646368-164383852300542270472373465-788-3335353821,013
Earnings Before Taxes-28.7%1,6532,3181,5881,3002,0312,4321,503-1527593,4381,8172,2641,814825-2,9732,0031,901-1,5012,4102,3501,016
EBT Margin-4.3%0.25*0.26*0.27*0.27*0.21*0.17*0.20*0.21*0.30*0.34*0.25*----------
Net Income-34.4%1,4302,1801,0451,0101,6401,7891,14419.003822,5921,5221,7291,551360-3,3391,5512,696-1,1651,8801,9753.00
Net Income Margin-2.6%0.21*0.21*0.20*0.21*0.17*0.12*0.15*0.16*0.23*0.27*0.19*----------
Free Cashflow19.7%1,9541,6332,1991,6352,3862,7061,6591,5933,0493,1142,197----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-0.4%62,12562,37362,33761,87663,17162,55762,87063,08067,95267,09867,98467,49268,40760,87855,93459,74161,62759,14663,21062,83763,675
  Current Assets0.7%16,08515,98014,28713,45614,44313,55413,17512,62914,77213,99113,92513,27815,99630,92624,64326,95030,29628,36133,72734,02435,836
    Cash Equivalents6.7%6,0855,7055,7044,9365,4124,6994,7394,2965,3384,3624,8934,0655,99712,8866,74610,05111,6319,47411,24016,92717,940
  Inventory7.5%1,7871,6631,6331,5761,5071,4631,4941,4821,6181,6761,7721,7791,6831,0081,052986922882884898814
  Net PPE-4.6%5,3175,5725,5405,4795,4755,3495,2995,2535,1215,0374,9964,9904,9674,8104,6534,5644,5024,3774,2494,1164,006
  Goodwill0%8,3148,3148,3148,3148,3148,3148,3148,3148,3328,3328,3348,3348,1084,1174,1174,1174,1174,1174,1174,1174,117
  Current Liabilities-5.6%11,28011,94513,96410,52811,23710,4239,2208,55811,61010,24510,2149,70511,3979,50910,5648,8799,7599,5678,9619,39710,605
  Long Term Debt0%23,18923,18921,20922,95622,95722,95325,19525,18325,17925,17527,91427,90728,64527,79221,10322,09822,09422,09024,08424,08024,574
    LT Debt, Non Current0%23,18923,18921,20922,95622,95722,95325,19525,18325,17925,17527,91427,90728,64527,79221,10322,09822,09422,09024,08424,08024,574
Shareholder's Equity2.3%22,83322,31421,09420,93921,24021,05720,21519,91521,06421,47119,71018,96418,22117,47118,14222,17922,65020,73622,75122,09121,534
  Retained Earnings1.9%16,30416,00215,13815,22315,68715,75615,11714,98616,32416,90315,39214,82114,38113,70914,44518,70919,38817,61619,82919,32619,024
  Additional Paid-In Capital3.5%6,5006,2796,0085,7935,5505,2265,0314,8674,6614,4924,2714,0923,8803,7123,5113,3113,0512,8702,6842,4942,282
Shares Outstanding-0.1%1,2461,2471,2471,2481,2471,2551,2561,2551,2561,2561,2561,256---------
Minority Interest-16.7%-84.00-72.00-64.00-58.00-31.00-24.00-21.00-12.00-5.001.007.0012.0019.0026.00115112125132135140147
Float---67,000---55,900---62,600---69,900---66,400--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations23.6%2,1691,7552,3381,7442,5672,8631,8021,8403,2053,2532,3162,6101,9162,2502,5661,4362,5802,6452,3421,5772,345
  Share Based Compensation-0.5%201202198165174168165130159171166139161173168141157162174143175
Cashflow From Investing-217.5%-727-229-483-826-375-713-308-1,070-278-234-577-2,042-8,977-271-5,023-344431-1,841-6,163-2442,735
Cashflow From Financing27.6%-1,099-1,519-1,101-1,406-1,554-2,118-1,003-1,794-1,942-3,527-931-2,4771314,124-874-2,611-896-2,515-1,857-2,366-1,670
  Dividend Payments-1.0%943953944969915929920945894900894917858861856874801804800817736
  Buy Backs-50.0%15030015040079218270.0035227.0018349.00309-22.5023862.001,32888.00252593834939
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

GILD Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Total revenues$ 27,116$ 27,281$ 27,305
Costs and expenses:   
Cost of goods sold6,4985,6576,601
Research and development expenses5,7184,9774,601
Acquired in-process research and development expenses1,155944939
In-process research and development impairments502,7000
Selling, general and administrative expenses6,0905,6735,246
Total costs and expenses19,51119,95117,387
Operating income7,6057,3309,918
Interest expense(944)(935)(1,001)
Other income (expense), net198(581)(639)
Income before income taxes6,8595,8148,278
Income tax expense(1,247)(1,248)(2,077)
Net income5,6134,5666,201
Net loss attributable to noncontrolling interest522624
Net income attributable to Gilead$ 5,665$ 4,592$ 6,225
Basic earnings per share attributable to Gilead (in dollars per share)$ 4.54$ 3.66$ 4.96
Shares used in basic earnings per share attributable to Gilead calculation (in shares)1,2481,2551,256
Diluted earnings per share attributable to Gilead (in dollars per share)$ 4.50$ 3.64$ 4.93
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)1,2581,2621,262
Product sales   
Revenues:   
Total revenues$ 26,934$ 26,982$ 27,008
Royalty, contract and other revenues   
Revenues:   
Total revenues$ 182$ 299$ 297

GILD Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 6,085$ 5,412
Short-term marketable debt securities1,179973
Accounts receivable, net4,6604,777
Inventories1,7871,507
Prepaid and other current assets2,3741,774
Total current assets16,08514,443
Property, plant and equipment, net5,3175,475
Long-term marketable debt securities1,1631,245
Intangible assets, net26,45428,894
Goodwill8,3148,314
Other long-term assets4,7924,800
Total assets62,12563,171
Current liabilities:  
Accounts payable550905
Accrued rebates3,8023,479
Other current liabilities5,1304,580
Current portion of long-term debt and other obligations, net1,7982,273
Total current liabilities11,28011,237
Long-term debt, net23,18922,957
Long-term income taxes payable2,0393,916
Deferred tax liability1,5882,673
Other long-term obligations1,2801,179
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding00
Common stock, par value $0.001 per share; 5,600 authorized; 1,246 and 1,247 shares issued and outstanding, respectively11
Additional paid-in capital6,5005,550
Accumulated other comprehensive income282
Retained earnings16,30415,687
Total Gilead stockholders’ equity22,83321,240
Noncontrolling interest(84)(31)
Total stockholders’ equity22,74921,209
Total liabilities and stockholders’ equity$ 62,125$ 63,171

About Gilead Sciences Inc

GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
 CEO
 WEBSITEgilead.com
 INDUSTRYPharmaceuticals
 EMPLOYEES17000

Gilead Sciences Inc Frequently Asked Questions

What is the ticker symbol for Gilead Sciences Inc? What does GILD stand for in stocks?

GILD is the stock ticker symbol of Gilead Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gilead Sciences Inc (GILD)?

As of Fri May 03 2024, market cap of Gilead Sciences Inc is 80.7 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GILD stock?

You can check GILD's fair value in chart for subscribers.

What is the fair value of GILD stock?

You can check GILD's fair value in chart for subscribers. The fair value of Gilead Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Gilead Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GILD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Gilead Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether GILD is over valued or under valued. Whether Gilead Sciences Inc is cheap or expensive depends on the assumptions which impact Gilead Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GILD.

What is Gilead Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, GILD's PE ratio (Price to Earnings) is 14.25 and Price to Sales (PS) ratio is 2.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GILD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Gilead Sciences Inc's stock?

In the past 10 years, Gilead Sciences Inc has provided 0.008 (multiply by 100 for percentage) rate of return.